Biotech and Pharmaceutical
News & Jobs
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  US Device


Market Summary

Company Profiles


Research Store

Biotech Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup


Astro-Med, Inc. (ALOT) Reports Second Quarter Sales and Earnings; Directors Declare Regular Cash Dividend

8/22/2012 9:31:57 AM

WEST WARWICK, RI--(Marketwire - August 21, 2012) -

Astro-Med, Inc. (NASDAQ: ALOT) reports Net Income of $987,000, equal to 13 cents per diluted share, on sales of $19,572,000 for the Second Quarter ended July 28, 2012. Unfavorable foreign exchange currency rates decreased this year's Second Quarter sales by approximately $459,000 or 2.3%, when compared to the previous year. The Company reported Net Income of $1,046,000, equal to 14 cents per diluted share, on sales of $20,336,000 for the comparable period of the prior year. Net Income in the prior year's Second Quarter includes income of $300,000, equal to 4 cents per diluted share related to the disposition on an insurance policy.

For the six months ended July 28, 2012, Astro-Med reported Net Income of $1,824,000, equal to 24 cents per diluted share, on sales of $37,997,000. Unfavorable foreign exchange currency rates decreased this year's six-month sales by approximately $668,000 or 1.8% when compared to the previous year. The current year's Net Income includes a tax benefit of $285,000 or $0.04 per diluted share, due to a favorable resolution of a previously uncertain tax position. During the comparable six-month period of the prior year, Net Income was $1,477,000, equal to 20 cents per diluted share, on sales of $39,196,000.

CEO Commentary

Commenting on the results, Everett V. Pizzuti, President and CEO, stated, "Astro-Med achieved another solid performance during the Second Quarter of Fiscal Year 2013. Customer demand again exceeded $19 million with new orders peaking at $19,886,000, a 2.3% increase over the previous year's restated orders received of $19,438,000 (excludes Astro-Med's divested Asheboro, NC label business), notwithstanding the current uncertain economic climate. As an outgrowth of the new orders trend, our Backlog rose 18.9% over the prior year-end level. Net Sales during the Quarter continued on a growth trajectory, with sales revenues rising 6.2% over the First Quarter's sales volume of $18,425,000.

"We received revenue contributions from each Product Group with QuickLabel Systems at $10,807,000, Grass Technologies at $4,909,000 and Test & Measurement, including Ruggedized Products, at $3,856,000. The growth in QuickLabel Systems was aided by the successful launch of the Company's latest innovation, a low cost inkjet label printer called the Kiaro!. The new Kiaro! is a revolutionary color label printer that combines high-speed label printing with near photographic print quality while ensuring an economical cost of ownership.

"We are also pleased with the Company's margin improvement during the Quarter. Our Gross Profit Margin rose 350 basis points over the prior year's Second Quarter Gross Profit Margin to 42.4%, while our Operating Margin rose 260 basis points from the previous year's Second Quarter Operating Margin to 8.6%. The improved Operating Margin is reflected in the Company's Operating Income of $1,678,000 in the Second Quarter, a 37.2% increase from the Operating Income reported in the prior year's Second Quarter.

"Astro-Med's financial position remains very strong as detailed on its Balance Sheet. Cash & Marketable Securities declined slightly to $22,516,000, our Working Capital Assets of Accounts Receivable and Inventories declined by less than 2% from the year-end levels and reflect turnover rates of 50 Days Sales Outstanding (DSO) and 112 Days of Inventory on Hand (DIOH)."

Astro-Med, Inc. Directors Declare Regular Cash Dividend

On August 20, 2012, the Directors of Astro-Med, Inc. declared the regular quarterly cash dividend of $0.07 per share, payable on October 4, 2012 to shareholders of record as of September 14, 2012.

Second Quarter Conference Call on Wednesday, August 22, 2012 at 11:00 am EDT

This call can be accessed at Astro-Med, Inc.'s web site at and is being webcast by Thomson Financial. You can participate in the conference call by dialing
1-877-941-0844 with passcode 4554178.

The Astro-Med, Inc. webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents ( a password-protected event management site.

Following the live broadcast, a webcast of the recorded call will be available for ten days at A telephone replay of the conference call will also be available for seven days by dialing 1-800-406-7325 with passcode 4554178.

                               Astro-Med, Inc                               
                   Consolidated Statements of Operations                    
                   In Thousands Except for Per Share Data                   
                                     Three-Months Ended   Six-Months Ended  
                                     July 28,  July 30,  July 28,  July 30, 
                                       2012      2011      2012      2011   
                                     --------  --------  --------  -------- 
Net Sales                              19,572  $ 20,336    37,997  $ 39,196 
Gross Profit                            8,299     7,901    15,670    15,402 
                                         42.4%     38.9%     41.2%     39.3%
Operating Expenses:                                                         
  Selling & Marketing                   4,298     4,526     8,542     9,092 
  Research & Development                1,208     1,187     2,411     2,655 
  General & Administrative              1,115       965     2,152     1,875 
                                     --------  --------  --------  -------- 
                                        6,621     6,678    13,105    13,622 
Operating Income                        1,678     1,223     2,565     1,780 
                                          8.6%      6.0%      6.8%      4.5%
Other Income (Expense), Net               (89)      297      (103)      448 
                                     --------  --------  --------  -------- 
Income Before Taxes                     1,589     1,520     2,462     2,228 
Income Tax Provision                      602       474       638       751 
                                     --------  --------  --------  -------- 
Net Income                           $    987  $  1,046  $  1,824  $  1,477 
                                     ========  ========  ========  ======== 
Net Income Per Share - Basic         $   0.13  $   0.14  $   0.25  $   0.20 
                                     ========  ========  ========  ======== 
Net Income Per Share - Diluted       $   0.13  $   0.14  $   0.24  $   0.20 
                                     ========  ========  ========  ======== 
Weighted Average Number of Common                                           
 Shares - Basic                         7,439     7,293     7,432     7,280 
Weighted Average Number of Common                                           
 Shares - Diluted                       7,491     7,446     7,489     7,424 
Dividends Declared Per Common Share  $   0.07  $   0.07  $   0.14  $   0.14 
                         Selected Balance Sheet Data                        
                                In Thousands                                
                                              As of               As of     
                                          July 28, 2012     January 31, 2012
Cash & Marketable Securities            $         22,516    $         23,040
Current Assets                          $         51,691    $         52,478
Total Assets                            $         65,804    $         67,062
Current Liabilities                     $          6,816    $          8,272
Shareholders' Equity                    $         56,354    $         55,663

About Astro-Med, Inc.

Astro-Med, Inc. is a leading manufacturer of specialty high tech printing systems, electronic medical instrumentation, and test and measurement data acquisition systems. Astro-Med, Inc. products are sold under the brand names Astro-Med®, Grass® Technologies, and QuickLabel® Systems, and are employed around the world in a wide range of aerospace, medical, military, industrial, and packaging applications. Astro-Med, Inc. is a member of the Russell Microcap® Index. Additional information is available by visiting

Safe Harbor Statement
This news release contains forward-looking statements, and actual results may vary from those expressed or implied herein. Factors that could affect these results include those mentioned in Astro-Med's FY2012 Annual Report and its annual and quarterly filings with the Securities and Exchange Commission.

Everett V. Pizzuti, CEO
Joseph P. O'Connell, CFO
Tel: 800-343-4039

Read at